Tags

Type your tag names separated by a space and hit enter

Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden.
Diabetes Ther. 2020 Aug; 11(8):1807-1820.DT

Abstract

AIMS

To explore persistence with insulin degludec/liraglutide (IDegLira) treatment, clinical characteristics and concomitant medications in a large population of patients in clinical practice.

METHODS

This was an observational study in patients with type 2 diabetes (n = 2432) who initiated IDegLira between 26 May 2015 and 31 December 2017. Data were obtained from Swedish nationwide registers and linked on an individual level using unique Swedish personal identifiers. Dose calculations were made for patients with ≥ 180 days between the first and last collections of IDegLira prescription. Changes in clinical parameters were evaluated as change from the last observation during 12 months prior to the initiation date until ± 90 days from the last collection of IDegLira.

RESULTS

Pre-index regimens (index date being the date of filling the first prescription of IDegLira) included: multiple daily insulin injections (45.1%); insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) (19.7%); long-acting insulins (11.8%); non-injectable therapy only (11.4%); GLP-1 RA only (9.8%); and no collection of diabetes medication during the 6-month pre-index period (2.3%). The majority of patients (94 and 84%) were persistent with IDegLira at 6 and 12 months, respectively. The most commonly used concomitant medication was metformin (69.4%). Mean daily dose was 33 dose steps. Overall, there was a mean decrease in HbA1c (approx. 10 mmol/mol [1%]) and body weight (- 1.1 kg). Improvements in HbA1c were observed regardless of pre-index treatment.

CONCLUSION

After 12 months, 84% of patients were persistent on IDegLira, with improved glycaemic control and reductions in body weight.

Authors+Show Affiliations

Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. bjorn.eliasson@gu.se. Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. bjorn.eliasson@gu.se.Centre of Registers Västra Götaland, Gothenburg, Sweden.Centre of Registers Västra Götaland, Gothenburg, Sweden.Novo Nordisk A/S, Søborg, Denmark.Medical Affairs, Novo Nordisk, Malmö, Sweden. Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.Novo Nordisk A/S, Søborg, Denmark.Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32617849

Citation

Eliasson, Björn, et al. "Persistence With IDegLira in Patients in Clinical Practice: a Nationwide Observational Study in Sweden." Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, vol. 11, no. 8, 2020, pp. 1807-1820.
Eliasson B, Ekelund J, Miftaraj M, et al. Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden. Diabetes Ther. 2020;11(8):1807-1820.
Eliasson, B., Ekelund, J., Miftaraj, M., Ranthe, M. F., Mårdby, A. C., Da Rocha Fernandes, J. D., & Svensson, A. M. (2020). Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, 11(8), 1807-1820. https://doi.org/10.1007/s13300-020-00872-4
Eliasson B, et al. Persistence With IDegLira in Patients in Clinical Practice: a Nationwide Observational Study in Sweden. Diabetes Ther. 2020;11(8):1807-1820. PubMed PMID: 32617849.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden. AU - Eliasson,Björn, AU - Ekelund,Jan, AU - Miftaraj,Mervete, AU - Ranthe,Mattis Flyvholm, AU - Mårdby,Ann-Charlotte, AU - Da Rocha Fernandes,João Diogo, AU - Svensson,Ann-Marie, Y1 - 2020/07/03/ PY - 2020/04/16/received PY - 2020/7/4/pubmed PY - 2020/7/4/medline PY - 2020/7/4/entrez KW - GLP-1 analogue KW - Insulin therapy KW - Liraglutide KW - Real-world KW - Type 2 diabetes SP - 1807 EP - 1820 JF - Diabetes therapy : research, treatment and education of diabetes and related disorders JO - Diabetes Ther VL - 11 IS - 8 N2 - AIMS: To explore persistence with insulin degludec/liraglutide (IDegLira) treatment, clinical characteristics and concomitant medications in a large population of patients in clinical practice. METHODS: This was an observational study in patients with type 2 diabetes (n = 2432) who initiated IDegLira between 26 May 2015 and 31 December 2017. Data were obtained from Swedish nationwide registers and linked on an individual level using unique Swedish personal identifiers. Dose calculations were made for patients with ≥ 180 days between the first and last collections of IDegLira prescription. Changes in clinical parameters were evaluated as change from the last observation during 12 months prior to the initiation date until ± 90 days from the last collection of IDegLira. RESULTS: Pre-index regimens (index date being the date of filling the first prescription of IDegLira) included: multiple daily insulin injections (45.1%); insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) (19.7%); long-acting insulins (11.8%); non-injectable therapy only (11.4%); GLP-1 RA only (9.8%); and no collection of diabetes medication during the 6-month pre-index period (2.3%). The majority of patients (94 and 84%) were persistent with IDegLira at 6 and 12 months, respectively. The most commonly used concomitant medication was metformin (69.4%). Mean daily dose was 33 dose steps. Overall, there was a mean decrease in HbA1c (approx. 10 mmol/mol [1%]) and body weight (- 1.1 kg). Improvements in HbA1c were observed regardless of pre-index treatment. CONCLUSION: After 12 months, 84% of patients were persistent on IDegLira, with improved glycaemic control and reductions in body weight. SN - 1869-6953 UR - https://www.unboundmedicine.com/medline/citation/32617849/Persistence_with_IDegLira_in_Patients_in_Clinical_Practice:_A_Nationwide_Observational_Study_in_Sweden L2 - https://dx.doi.org/10.1007/s13300-020-00872-4 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.